Vedanta Biosciences, a Cambridge, MA-based clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, raised $16.6m in Series C-2 financing.
The round, which brought the total capital raised in its Series C and C-2 round to $62.1m, included QUAD Investment Management, SV Investment Corp., Shinhan Investment-Private Equity, Shinhan Capital-Yeollim Partners, Partners Investment Co., Ltd, FC Capital, and SymBiosis LLC, who joinef previously announced Series C investors, including the Bill & Melinda Gates Foundation, Bristol-Myers Squibb, Rock Springs Capital, JSR Corporation, Shumway Capital, Invesco Asset Management, Health for Life (Seventure Partners), and founder PureTech Health.
The funding further supports the expansion of the company’s broad clinical pipeline, including:
– the recently launched Phase 1b/2 study of VE416 in food allergy,
– a planned Phase 1b/2 study of VE800 and OPDIVO® (nivolumab) in advanced or metastatic cancers, and
– the ongoing Phase 2 study of VE303 in recurrent Clostridioides difficile infection (rCDI).
Led by Bernat Olle, Ph.D., co-founder and chief executive officer, Vedanta Biosciences is a clinical-stage microbiome leader developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria. Its proprietary capabilities include a large collection of human-gut associated bacteria, assays and bioinformatics techniques for consortia design and optimization, vast datasets from human interventional studies and facilities for cGMP-compliant manufacturing of rationally-defined bacterial consortia in powder form.
The company’s work, in collaboration with its scientific co-founders, has led to the identification of human commensal bacteria that induce a range of immune responses – including induction of regulatory T cells, CD8+ T cells, and Th17 cells, among others. Vedanta Biosciences has harnessed these biological insights and its capabilities to generate a pipeline of investigational live biotherapeutic products (LBPs) in infectious disease, autoimmune disease, allergy, and immuno-oncology. This pipeline includes three clinical-stage product candidates currently being evaluated for the treatment of recurrent C. difficile infection and inflammatory bowel disease (in collaboration with Janssen Biotech, Inc.), and food allergy, as well as a fourth product candidate expected to enter the clinic in 2019 in patients with advanced or metastatic cancers (in combination with Bristol-Myers Squibb’s checkpoint inhibitor OPDIVO®).
The company’s IP portfolio contains over 30 issued patents with coverage extending to 2037. Vedanta Biosciences was founded by PureTech Health (LSE:PRTC). Its scientific co-founders are world-renowned experts in immunology and microbiology who have pioneered the fields of innate immunity, Th17 and regulatory T cell biology.